Current Diagnosis and Management of Abetalipoproteinemia

J Atheroscler Thromb. 2021 Oct 1;28(10):1009-1019. doi: 10.5551/jat.RV17056. Epub 2021 May 16.


Abetalipoproteinemia (ABL) is a rare autosomal recessive disorder caused by biallelic pathogenic mutations in the MTTP gene. Deficiency of microsomal triglyceride transfer protein (MTTP) abrogates the assembly of apolipoprotein (apo) B-containing lipoprotein in the intestine and liver, resulting in malabsorption of fat and fat-soluble vitamins and severe hypolipidemia. Patients with ABL typically manifest steatorrhea, vomiting, and failure to thrive in infancy. The deficiency of fat-soluble vitamins progressively develops into a variety of symptoms later in life, including hematological (acanthocytosis, anemia, bleeding tendency, etc.), neuromuscular (spinocerebellar ataxia, peripheral neuropathy, myopathy, etc.), and ophthalmological symptoms (e.g., retinitis pigmentosa). If left untreated, the disease can be debilitating and even lethal by the third decade of life due to the development of severe complications, such as blindness, neuromyopathy, and respiratory failure. High dose vitamin supplementation is the mainstay for treatment and may prevent, delay, or alleviate the complications and improve the prognosis, enabling some patients to live to the eighth decade of life. However, it cannot fully prevent or restore impaired function. Novel therapeutic modalities that improve quality of life and prognosis are awaited. The aim of this review is to 1) summarize the pathogenesis, clinical signs and symptoms, diagnosis, and management of ABL, and 2) propose diagnostic criteria that define eligibility to receive financial support from the Japanese government for patients with ABL as a rare and intractable disease. In addition, our diagnostic criteria and the entry criterion of low-density lipoprotein cholesterol (LDL-C) <15 mg/dL and apoB <15 mg/dL can be useful in universal or opportunistic screening for the disease. Registry research on ABL is currently ongoing to better understand the disease burden and unmet needs of this life-threatening disease with few therapeutic options.

Keywords: Abetalipoproteinemia; Chylomicron; Fat-soluble vitamin; Hypolipidemia; MTTP; VLDL.

Publication types

  • Review

MeSH terms

  • Abetalipoproteinemia / blood
  • Abetalipoproteinemia / diagnosis*
  • Abetalipoproteinemia / pathology
  • Abetalipoproteinemia / therapy*
  • Apolipoproteins B / blood
  • Cholesterol, LDL / blood
  • Cost of Illness
  • Disease Management
  • Humans
  • Prognosis


  • Apolipoproteins B
  • Cholesterol, LDL